奥浦迈: 上海市方达律师事务所关于上海奥浦迈生物科技股份有限公司2023年限制性股票激励计划调整授予价格、作废部分限制性股票及首次授予部分第二个归属期与预留授予部分第一个归属期归属相关事项的法律意见书

Core Viewpoint - The legal opinion letter from Fangda Partners addresses the adjustments to the stock incentive plan of Shanghai Aopumai Biotechnology Co., Ltd., including the adjustment of grant prices, the cancellation of unvested shares, and the confirmation of vesting conditions for certain stock grants [1][6][19]. Summary by Sections Legal Framework - The legal opinion is based on various Chinese laws and regulations, including the Company Law, Securities Law, and specific guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange [2][3]. Price Adjustment - The stock grant price for the incentive plan was adjusted from 25.00 CNY per share to 24.14 CNY per share, following the calculation of dividends distributed to shareholders [10][11][19]. Cancellation of Shares - A total of 35,000 shares were confirmed to be canceled due to the departure of two incentive recipients who no longer qualified for the incentive program [12][13][19]. Vesting Conditions - The vesting conditions for the first grant's second vesting period and the reserved grant's first vesting period have been met, confirming a total of 297,800 shares eligible for vesting, with 264,000 shares from the first grant and 33,800 shares from the reserved grant [18][19].